newsfilter
← Latest News
PR Newswire·

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

BRUSSELS, April 23, 2021 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that 12 abstracts on bimekizumab, an investigational IL-17A and IL-17F inhibitor, in the treatment of adults with moderate to severe plaque psoriasis, will